<DOC>
	<DOCNO>NCT01209715</DOCNO>
	<brief_summary>In present study , investigator wish address effect glucocorticoid/long-acting beta-agonist preparation endothelial function COPD patient currently smoke ( ex-smokers ) measure endothelium-dependent ( albuterol response ) endothelium-independent ( NTG response ) vasodilation bronchial artery , reflect endothelium-dependent endothelium-independent vasodilation ( drug-induced increase Qaw , ΔQaw ) . With approach investigator test hypothesis stable ICS-naïve COPD patient , endothelium-dependent vasodilation restore glucocorticoid/long-acting beta-agonist preparation , presumably result glucocorticoid component .</brief_summary>
	<brief_title>Effect Inhaled Glucocorticoid-long-acting Beta Adrenergic Agonist Endothelial Function COPD</brief_title>
	<detailed_description>To test premise characterize time dependence response , investigator propose follow two aim : 1 . To determine effect medium dose glucocorticoid/long-acting beta-agonist preparation ( 250 μg fluticasone plus 50 μg salmeterol ) administer 3 week inhale albuterol sub-lingual NTG induce vasodilation bronchial artery , assess ΔQaw stable glucocorticoid-naïve COPD patient , re-assess response 3 week glucocorticoid/long-acting beta-agonist washout period . 2 . To determine inhaled albuterol sub-lingual NTG-induced vasodilation ( ΔQaw ) , 30 min 120 min single medium dose ICS ( 220 μg fluticasone ) stable glucocorticoid- naïve COPD patient . For aim , protocol design placebo-controlled double-blind . For second aim , fluticasone pretreatment possible salmeterol component fluticasone/salmeterol combination preparation could influence albuterol responsiveness irrespective glucocorticoid effect . The timing endothelial function measurement long-term glucocorticoid/long-acting beta-agonist protocol single dose ICS protocol base past experience ICS airway vascular function . Single dose effect see within 15-30 min wan 90 min ( 25,26 ) , long-term treatment effect longer see 3 week ICS withdrawal ( 16 ) .</detailed_description>
	<mesh_term>Glucocorticoids</mesh_term>
	<mesh_term>Fluticasone Propionate , Salmeterol Xinafoate Drug Combination</mesh_term>
	<mesh_term>Adrenergic Agents</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<mesh_term>Adrenergic Agonists</mesh_term>
	<mesh_term>Adrenergic beta-Agonists</mesh_term>
	<criteria>Smoking history least 10 packyears quit smoke least 1 year study . Diagnosis COPD Postbronchodilator FEV1 le 75 % predict FEV1/FVC ratio le 0.7 ( GOLD stage ≥2 ) . At entry study , subject clinically stable ; allow use shortacting longacting β2 adrenergic agonist cholinergic antagonist usual airway medication . Women childbearing potential use accept birth control measure ; pregnant breast feed woman . Use cardiovascular medication hold study day Use oral airway medication antiinflammatory agent Subjects know betaadrenergic agonist NTG intolerance Acute respiratory infection within four week prior study A body mass index &gt; 30</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>airway blood flow ,</keyword>
	<keyword>COPD ,</keyword>
	<keyword>endothelial dysfunction</keyword>
	<keyword>inhaled corticosteroid</keyword>
</DOC>